Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Other Non Operating Income (2023 - 2025)

Historic Other Non Operating Income for Immunocore Holdings (IMCR) over the last 3 years, with Q3 2025 value amounting to $5.1 million.

  • Immunocore Holdings' Other Non Operating Income fell 4351.71% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 119500.34%. This contributed to the annual value of $14.2 million for FY2024, which is 20775.65% up from last year.
  • Latest data reveals that Immunocore Holdings reported Other Non Operating Income of $5.1 million as of Q3 2025, which was down 4351.71% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Other Non Operating Income ranged from a high of $11.2 million in Q3 2023 and a low of -$12.5 million during Q4 2023
  • Moreover, its 3-year median value for Other Non Operating Income was $4.4 million (2024), whereas its average is $1.3 million.
  • Examining YoY changes over the last 5 years, Immunocore Holdings' Other Non Operating Income showed a top increase of 32730.67% in 2025 and a maximum decrease of 4351.71% in 2025.
  • Quarter analysis of 3 years shows Immunocore Holdings' Other Non Operating Income stood at -$12.5 million in 2023, then skyrocketed by 107.96% to $993000.0 in 2024, then soared by 409.77% to $5.1 million in 2025.
  • Its Other Non Operating Income was $5.1 million in Q3 2025, compared to $4.7 million in Q2 2025 and $5.5 million in Q1 2025.